



## Rheumatoid Arthritis and Other Inflammatory Diseases: From Pathogenesis through Therapeutic Targets to Personalized Medicine

Guest Editor:

**Dr. Agnieszka  
Paradowska-Gorycka**

Department of Molecular Biology,  
National Institute of Geriatrics,  
Rheumatology and  
Rehabilitation, Warsaw, Poland

agnieszka.paradowska-gorycka@  
spartanska.pl

Deadline for manuscript  
submissions:

**31 January 2021**

### Message from the Guest Editor

Dear Colleagues,

Arthritis, as well as inflammation, is a common health problem in the global population affecting millions of people, and a leading cause of disability. Every day, patients with rheumatoid arthritis or other inflammatory diseases take drugs without efficient results. Early diagnosis of these patients is significant inasmuch as primary treatment can be started better. Appropriate selection of convenient and safe therapy may be an effective tool not only to relieve symptoms of the disease but also to improve the length and quality of life, and for the remission of the disease. The reason for this variability between individuals is unclear, but it leads to studies identifying biomarkers predictive of the treatment response. There is a huge demand for reliable biomarkers associated with response to biological treatments to improve reactivity and reduce treatment costs. Pharmacogenetic and pharmacogenomic studies, which help to determine the genetic profile of individual patients, may bring us closer to personalized medicine.

